A carregar...
Prexasertib (LY2606368) reduces clonogenic survival by inducing apoptosis in primary patient‐derived osteosarcoma cells and synergizes with cisplatin and talazoparib
Progress in the systemic control of osteosarcoma has been limited over the past decades thus indicating the urgent clinical need for the development of novel treatment strategies. Therefore, we have recently developed new preclinical models to study promising novel agents for the treatment of pediat...
Na minha lista:
| Publicado no: | Int J Cancer |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons, Inc.
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7384073/ https://ncbi.nlm.nih.gov/pubmed/31782150 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.32814 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|